Folkehelseinstituttet Due Diligence

Run due diligence on Folkehelseinstituttet: check compliance and get alerts when suppliers or ownership change.

Norway · owned by Norwegian Government (Norway) · fhi.no · 26 vendors

Folkehelseinstituttet (Norwegian Institute of Public Health) is Norway's national public health institute with responsibilities including infectious disease control, mental and physical health, environmental medicine, epidemiology and substance abuse. The organization conducts health surveillance, research, and provides expert advice to support public health policy in Norway.

Resilience scores

Technology vendors

Insights

Last updated 2026-02-17 · revision 14

26 direct vendors, 245 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

6 in-scope frameworks identified; showing 3.

Norwegian Security Act — No public evidence

FHI likely falls under this act as an operator of critical national health infrastructure and sensitive government information systems.

NIS2 (source) — No public evidence

FHI operates in the health sector as an Essential Entity, providing critical public health services and maintaining health registries.

GDPR (source) — No public evidence

FHI is located in Norway (EEA member) and processes extensive personal data including health records, epidemiological data, and registry information.

Financials

Three-year financials

Financial Resilience Score: 8/10

Folkehelseinstituttet (NIPH) is a state-owned administrative body under the Norwegian Ministry of Health and Care Services, providing it with high financial security through government budget allocations. The institute saw significant revenue volatility between 2021 and 2024, primarily driven by the conclusion of emergency COVID-19 funding and a major 2024 reorganization that transferred several regulatory functions to the Norwegian Directorate of Health. Despite these budget reductions, NIPH remains a core national institution with an essential mandate. The institute's resilience is bolstered by its diversified funding model, which includes substantial external grants from the Research Council of Norway and the European Union. Although it underwent a period of downsizing in 2023 to adjust to lower post-pandemic budgets, the integration of new departments (such as the Cancer Registry of Norway) in 2024 has stabilized its workforce and expanded its strategic importance as a knowledge and data hub for the Norwegian health sector.

Key strengths: Stable state budget allocations, Critical national mandate for health data and infection control, Strong track record in securing international research grants, High organizational expertise and public trust

Risk factors: Vulnerability to political restructuring and mandate shifts, Phasing out of large-scale pandemic-related funding, Recent cost-cutting measures and staff reductions in 2023

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report